Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.

Anna Dittrich Erik WestmanSara ShamsTobias SkillbäckHenrik Zetterberg Kaj BlennowAnna ZettergrenIngmar SkoogSilke Kern

Published in: Neurology (2024)

Information on proportion of individuals eligible for AD treatment with lecanemab in the general public is limited. We provide information on 70-year-olds in Sweden and extrapolate these data to Europe and the United States. This study opens for larger studies on this proportion and implementation of lecanemab treatment.

Keyphrases

community dwelling
healthcare
primary care
mental health
physical activity
health information
emergency department
pregnant women
electronic health record
combination therapy
machine learning
quality improvement
big data
adverse drug
pregnancy outcomes